Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System
Cancer Medicine · 2026
DOI: 10.1002/cam4.71467 ↗At a glance
Übersichtsarbeit in Cancer Medicine, 2026. Written by Mina Nikanjam and 9 co-authors. Institution: Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA. Major MEDLINE topics: Inducible T-Cell Co-Stimulator Protein, Inducible T-Cell Co-Stimulator Ligand, Neoplasms. Cited 11 times so far (Crossref); 99 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Background
ICOS (inducible T‐cell co‐stimulator) and ICOS ligand (ICOSL) are part of an important, complex pathway that can lead to both immune stimulation and suppression. ICOS and ICOSL have heterogeneous expression patterns between and within tumor types.
Methods
This review provides an overview of ICOS and ICOSL, their mechanisms of action, expression in cancer and other diseases, and clinical trials exploring therapies targeting ICOS.
Results
Because of the bidirectional immune impact of the ICOS/ICOSL signaling pathway, both ICOS agonists and antagonists are under development and evaluation in clinical trials. The majority of clinical trials have focused on the development of ICOS agonists, with only one study exploring an ICOS antagonist; there have been no clinical trials developing ICOSL agonists or antagonists in oncology. ICOS can be expressed on immune‐activating effector T‐cell and immunosuppressive regulatory T‐cell (Tregs). Thus, it is critical to determine where and how ICOS is expressed in order to evaluate the role for agonists versus antagonists. To date, ICOS agonists have shown limited activity in patients with malignancies, perhaps because of the lack of biomarker‐based trials. However, an ICOS antagonist demonstrated a 44% response rate in angioimmunoblastic T‐cell lymphoma; ICOS is highly expressed on T‐follicular helper cells (type of CD4 cell) and proliferation of these cells may be a pathogenic mechanism for these lymphomas. A role for the ICOS/ICOSL signaling pathway has also been implicated outside of oncology, including in viral infections such as COVID‐19, and in autoimmune conditions such as asthma and systemic lupus erythematosus.
Conclusion
Biomarker‐driven approaches will be important to individualize therapy and ascertain which cancer patients will derive the greatest benefit from ICOS‐directed combination therapy approaches.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA.
- Department of Hematology and Oncology, Dartmouth Cancer Center, Lebanon, New Hampshire, USA.
- OmniSeq (Labcorp) Inc., Buffalo, New York, USA.
- Labcorp Oncology, Durham, North Carolina, USA.
- Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, California, USA.
- Medical College of Wisconsin, Cancer Center, Milwaukee, Wisconsin, USA.
ORCID profiles: Mina Nikanjam, Aung Naing
Funding
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Nikanjam, M., Kato, S., Nishizaki, D., Miyashita, H., Pabla, S., Nesline, M. K., Ko, H., Conroy, J. M., Naing, A., & Kurzrock, R. (2026). Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System. Cancer Medicine. https://doi.org/10.1002/cam4.71467
Vancouver
Nikanjam M, Kato S, Nishizaki D, Miyashita H, Pabla S, Nesline MK, et al. Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System. Cancer Medicine. 2026. doi:10.1002/cam4.71467
BibTeX
@article{Nikanjam2026,
author = {Nikanjam, Mina and Kato, Shumei and Nishizaki, Daisuke and Miyashita, Hirotaka and Pabla, Sarabjot and Nesline, Mary K and Ko, Heidi and Conroy, Jeffrey M and Naing, Aung and Kurzrock, Razelle},
title = {Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71467}
}
EUVIMED